Micronized Progesterone

Wendy S. Wetzel
In: The Nurse Practitioner · 1999 · vol. 24(5) , pp. 62???77 · doi:10.1097/00006205-199905000-00005 · PMID:10349670 · W1971534607
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-20 · read from full text ⓘ

This article reviews the therapeutic indications for oral micronized progesterone, highlighting its status as a safe and well-tolerated alternative to synthetic progestational agents following FDA approval. The author illustrates the drug's utility through five case studies that address patient compliance, individualized treatment planning, and the importance of patient partnership in achieving beneficial health outcomes. The text emphasizes that this new option offers improved acceptance compared to previous treatments which were often limited by adverse effects. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Although progestational agents have been widely used for gynecologic conditions, treatment options have usually been limited to synthetic agents with adverse effects and sparse patient acceptance. Recent Food and Drug Administration approval of oral micronized progesterone (MP) has introduced therapy with a safe, effective, well-tolerated drug. This article reviews therapeutic indications for MP as illustrated in five case studies. Issues of patient compliance, individualized treatment plans, and patient partnership to obtain the most beneficial outcomes are discussed.
Full text 799 characters · extracted from oa-doi-fallback · click to expand
Article: PDF Only Micronized Progesterone A New Option for Women's Health Care - WENDY WETZEL The Nurse Practitioner 24(5):p 62-77, May 1999. Although progestational agents have been widely used for gynecologic conditions, treatment options have usually been limited to synthetic agents with adverse effects and sparse patient acceptance. Recent Food and Drug Administration approval of oral micronized progesterone (MP) has introduced therapy with a safe, effective, well-tolerated drug. This article reviews therapeutic indications for MP as illustrated in five case studies. Issues in five case studies. Issues of patient compliance, individualized treatment plans, and patient partnership to obtain the most beneficial outcomes are discussed. Copyright © 1999 Lippincott Williams & Wilkins, Inc.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK